Clinical efficacy of combined use of physical training and a fixed combination of an angiotensin receptor blocker II - valsartanumand the calcium antagonist - amlodipine on ambulatory (III) stage of rehabilitation in smoking patients with comorbid diseases (coronary heart disease, hypertension and chronic obstructive pulmonary disease)
- 作者: Bubnova M.1, Sulim Y.2, Aronov D.1, Novikova N.1, Vygodin V.1, Meshcheryakova N.3
-
隶属关系:
- State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation
- Nordic Health Center
- Research Institute of pulmonology FMBA of Russia
- 期: 卷 7, 编号 2 (2016)
- 页面: 29-41
- 栏目: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45227
- DOI: https://doi.org/10.26442/CS45227
- ID: 45227
如何引用文章
全文:
详细
作者简介
M. Bubnova
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation
Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3
Yu. Sulim
Nordic Health Centerврач-кардиолог отд-ния кардиологии и функциональной диагностики ООО «Скандинавский центр здоровья» 111024, Russian Federation, Moscow, ul. 2-ia Kabel’naia, d. 2, str. 25
D. Aronov
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federationд-р мед. наук, проф., рук. лаб. кардиологической реабилитации ФГБУ ГНИЦ ПМ, засл. деят. науки РФ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3
N. Novikova
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federationканд. пед. наук, ст. науч. сотр. лаб. кардиологической реабилитации отд. реабилитации и вторичной профилактики сочетанной патологии ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3
V. Vygodin
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federationвед. науч. сотр. ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3
N. Meshcheryakova
Research Institute of pulmonology FMBA of Russiaканд. мед. наук, ст. науч. сотр. лаб. легочной реабилитации и исследования состояния здоровья легочных больных ФГУ НИИ пульмонологии 105077, Russian Federation, Moscow, ul. 11-ia Parkovaia, d. 32
参考
- Balkissoon R, Lommatzsch S, Carolan B, Make B. Chronic obstructive pulmonary disease: a concise review. Med Clin North Am 2011; 95: 1125-41.
- Sidney S, Sorel M, Quesenberry C.P et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-75.
- Holguin F, Folch E, Redd S.C et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-11.
- Selvaraj C.L, Gurm H.S, Gupta R et al. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96: 756-9.
- Kjoller E, Kober L, Iversen K, Torp-Pedersen C. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Fail 2004; 6: 71-7.
- Salisbury A.C, Reid K.J, Spertus J.A. Impact of chronic obstructive pulmonary disease on post - myocardial infarction outcomes. Am J Cardiol 2007; 99: 636-41.
- Iribsrren C, Tecawa I.S, Sydney S, Friedman G.D. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 1999; 343: 1773-80.
- Anthonisen N.R, Connett J.E, Enright P.L et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease 2013. Available from: http://www.goldcopd.org/uploads/users /files/GOLD_Report_2013_Feb20.pdf. Accessed July 20, 2013.
- Vestbo J, Hurd S.S, Agusti A.G et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187 (4): 347-65.
- Barnes P.J, Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33 (5): 1165-85.
- American Thoracic Society, European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999; 159 (4 Pt. 2): S1-S40.
- Wust R.C, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 289-300.
- Whittom F, Jobin J, Simard P.M et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998; 30 (10): 1467-74.
- Gosker H.R, Zeegers M.P, Wouters E.F, Schols A.M. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta - analysis. Thorax 2007; 62 (11): 944-9.
- Jobin J, Maltais F, Doyon J.F et al. Chronic obstructive pulmonary disease: capillarity and fiber - type characteristics of skeletal muscle. J Cardiopulm Rehabil 1998; 18 (6): 432-37.
- Barreiro E, Gea J, Corominas J M, Hussain S N. Nitric oxide syntheses and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2003; 29 (6): 771-8.
- Gosker H R, Hesselink M K, Duimel H et al. Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007; 30 (1): 73-9.
- Maltais F, Simard A A, Simard C et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996; 153 (1): 288-93.
- Johnston K, Grimmer-Somers K. Pulmonary rehabilitation: overwhelming evidence but lost in translation? Physiother Can 2010; 62: 368-73.
- Ли В.В., Задионченко В.С., Адашева Т.В. и др. Хроническая обструктивная болезнь легких и артериальная гипертония - метафизика и диалектика//CardioСоматика. 2013; 1: 5-10.
- Адашева Т.В., Федорова И.В., Задионченко В.С. и др. Антигипертензивная терапия у больных хронической обструктивной болезнью легких: преимущества антагонистов кальция. Рациональная фармакотер. в кардиологии. 2008; 5: 39-45.
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). www.goldcopd.com.
- Devereux R.A, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-8.
- Johnston K, Grimmer-Somers K. Pulmonary rehabilitation: overwhelming evidence but lost in translation? Physiother Can 2010; 62: 368-73.
- Fischer M.J, Scharloo M, Abbink J.J et al. Drop - out and attendance in pulmonary rehabilitation: the role of clinical and psychosocial variables. Respir Med 2009; 103: 1564-71.
- Garrod R, Marshall J, Barley E, Jones P.W. Predictors of success and failure in pulmonary rehabilitation. Eur Respir J 2006; 27: 788-94.
- Sabit R, Griffiths T.L, Watkins A.J et al. Predictors of poor attendance at an outpatient pulmonary rehabilitation programme. Respir Med 2008; 102: 819-24.
- Bustamante M.J, Valentino G, Kramer V et al. Patient Adherence to a ardiovascular Rehabilitation Program: What Factors Are Involved? Int J Clin Med 2015; 6: 605-14.
- Turk-Adawi K.I, Oldridge N.B, Tarima S.S et al. Cardiac Rehabilitation Enrollment Among Referred Patients. Рatient and organizational factors. J Cardiopulmon Rehabilit Prevent 2014; 34: 114-22.
- Hassan H.A, Aziz N.A, Hassan Y, Hassan F. Does the duration of smoking cessation have an impact on hospital admission and health - related quality of life amongst COPD patients? Int J COPD 2014; 9: 493-9.
- Бубнова М.Г., Аронов Д.М., Сулим Ю.Н., Выгодин В.А. Клиническая эффективность фиксированной комбинации блокатора рецепторов к ангиотензину II валсартана с антагонистом кальция амлодипином у курящих больных с ССЗ и хронической обструктивной болезнью легких//CardioСоматика. 2015; 1: 24-35.
- Baessler A, Hengstenberg C, Holmer S et al. Long - term effects of in - hospital cardiac rehabilitation on the cardiac risk profile. A case - control study in pairs of siblings with myocardial infarction. Eur Heart J 2001; 22: 1111-8.
- Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 2004; 364: 937-52.
- Prugger Ch, Wellmann J, Heidrich J et al, on behalf of the EUROASPIRE Study Group. Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J 2014; 35: 590-8. doi: 10.1093/eurheartj/eht538.
- Sturchio A, Gianni A.D, Campana B et al. Coronary Artery RIsk Management Programme (CARIMAP) Delivered by a Rehabilitation Day - Hospital. Impact on patients with coronary artery disease. J Cardiopulmon Rehabilitat Prevent 2012; 32: 386-93.
- Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta - analysis of randomised trials. BMJ 2008; 336: 1121-3.
- Бубнова М.Г., Сеченова Е.В., Аронов Д.М. Оценка эффективности ранней комплексной постстационарной реабилитации больных коронарной болезнью сердца после вмешательств на коронарных сосудах на диспансерно - поликлиническом этапе Эффективная фармакотер. в кардиологии и ангиологии. 2011; 1: 86-91.
- Аронов Д.М., Красницкий В.Б., Бубнова М.Г. и др. Физические тренировки в комплексной реабилитации и вторичной профилактике на амбулаторно - поликлиническом этапе у больных ишемической болезнью сердца после острых коронарных осложнений. Российское кооперативное исследование. Кардиология. 2006; 9: 33-8.
- Аронов Д.М., Бубнова М.Г., Красницкий В.Б. и др. от имени исследователей. Клинические эффекты годичной программы физических тренировок у больных АГ трудоспособного возраста, перенесших острый инфаркт миокарда. Российское рандомизированное контролируемое клиническое исследование. Системные гипертензии. 2015; 12 (4): 61-8.
- Aronov D.M, Bubnova M.G, Anzimirova N.V, Novikova N.K. Clinical efficacy of physical rehabilitation program in patients after myocardial infarction complicated by congestive heart failure. Eur J Heart Failure 2015; 17 (Suppl. 1): 109. doi: 10.1002/ejhf.277.
- Bubnova M.G, Aronov D.M, Krasnitsky V.B et al. Effectiveness of physical rehabilitation program in hypertensive patients after acute myocardial infarction (A COOPERATIVE RUSSIAN TRIAL). J Hypertension 2014; 32 (e-Suppl. 1): e420.
- Awad-Elkarim A.A, Bagger J.P, Albers C.J et al. A prospective study of long term prognosis in young myocardial infarction survivors: the prognostic value of angiography and exercise testing. Heart 2003; 89: 843-7.
- Verdecchia P, Schilaci G, Borgioni C et al. Adverse prognosis significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-8.
- Hole D.J, Watt G.C, Davey-Smith G et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-5; discussion 715-716.
- Seeger H, Mueck A.O, Lippert T.H. Effects of valsartan and 17-beta - estradiol on the oxidation of low - density lipoprotein in vitro. Coron Artery Dis 2000; 11: 347-9.
- Tsutamoto T, Wada A, Maeda K et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin 6 and solubile adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000; 35: 714-21.
- Mancini G.B.J, Etminan M, Zhang B et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease JACC 2006; 47 (12): 2554-60.
- Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001; 141 (2): 49-57.
![](/img/style/loading.gif)